[Treatment of anemia in chronic renal failure (predialysis)].
The treatment of renal anaemia with human recombinant erythropoietin (r-hu-EPO) in predialysis patients requires a close collaboration between the general practitioner and the nephrologist. This therapeutic option, along with other measures as part of the management of patients with renal insufficiency, is aimed at slowing down the progression of the kidney failure and at maintaining the patient in the best possible metabolic conditions. This paper summarises the benefits and risks of r-hu-EPO administered in renal insufficiency. The practical guidelines for the r-hu-EPO administration should help to assure an optimal and cost-effective utilization of the treatment.